Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Torrent Pharmaceuticals - Domestic outperforms; margin sustains - ICICI Securities

Posted On: 2020-10-26 23:01:41

Torrent Pharma's (Torrent) Q2FY21 performance was mixed with reported revenue below estimates but lower cost boosting EBITDA above estimates. Revenue remained flat YoY with international markets declining 6% offset by 7% growth in domestic market. US sales declined 9.3% QoQ to US$43mn vs estimated US$48mn. Controlled costs aided 450bps jump in EBITDA margin to 31.5% (I-Sec: 29.5%). Adjusted PAT grew strong 27.0% to Rs3.1bn, as estimated driven by better margin and lower interest expense. We are positive on the long-term outlook considering growth improvement in India business with chronic segment dominance, potential resolution of OAI status at two facilities in FY21E, EPS CAGR of 23.0% over FY20-FY23E and strengthening balance sheet with improving FCF generation. Retain ADD.

- India continues to grow, US underperforms: India business grew 7.1% vis-a-vis ~1% growth in the industry. Company should continue to outpace industry in terms of growth considering its significant exposure to the chronic segment and established product portfolio. US revenues declined 9.3% QoQ to US$43mn due to temporary discontinuation of sartans, price erosion and absence of new launches. Brazil revenues declined 17.3% YoY due to currency depreciation despite constant currency growth of 5%. Germany revenues grew 4.4% YoY and has largely completed installing new SOPs at its warehouse. RoW business and CRAMS grew 3.1% YoY and 10.3% YoY respectively.

- Controlled costs aid EBITDA margin: EBITDA margin improved 450bps YoY but declined 60bps QoQ to 31.5%, ahead of our estimates, despite gross margin dropping 70bps YoY and 150bps QoQ to 72.5%. This improvement in EBITDA was supported by lower S,G&A and R&D expenditure. We believe expense base would increase from current levels but still be lower than FY20. Overall, we expect 420bps EBITDA margin improvement over FY20-FY23E to 31.5%, driven by strong growth in India and operating leverage.

- Outlook: We estimate revenue and earnings to CAGRs at 7.6% and 23.0% respectively, over FY20-FY23E led by higher India growth (10.4% CAGR). Return ratios dropped in FY19 post Unichem acquisition, but we expect RoE and RoCE to reach 26.0% and 21.4%, respectively, by FY23E. We also expect the company to repay Rs20bn debt over next two years which would bring down net debt to EBITDA comfortably lower than 1x by FY23E.

- Valuations and risks: We reduce revenue and EPS estimates by 3-4% and 0-3% respectively for FY21-FY23E to factor in lower sales in the export business and reduced expenses. We maintain ADD with a revised target price of Rs3,014/share based on 18xSep'22E EV/EBITDA (earlier: Rs3,080/share). Key downside risks: Delay in resolution of FDA issues and forex volatility.

Shares of TORRENT PHARMACEUTICALS LTD. was last trading in BSE at Rs.2654.45 as compared to the previous close of Rs. 2734.35. The total number of shares traded during the day was 23676 in over 2381 trades.

The stock hit an intraday high of Rs. 2773.85 and intraday low of 2644. The net turnover during the day was Rs. 63804283.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Initiating Coverage on Godrej Properties - The housing factory - HDFC Securities

Burger King IPO - Angel Broking

Rollover Analysis - Record foreign inflows pushes Nifty to 13k - YES Securities

Ceramic tiles industry - Market share gains sustain for top branded players - ICICI Securities

Gas sector - CGD: Competition to hit margins, volumes and lead to derating - ICICI Securities

Cement - Prices resilient in Q3; consensus upgrades to continue - ICICI Securities

Specialty chemicals - Price trend in Sep-20 - ICICI Securities

Timken India - Q2FY21 Company Update - ICICI Direct

Upgrade in target price of IDFC First Bank - Angel Broking

Laurus Labs stake acquisition in Richore Lifesciences - Angel Broking

Shares of Lakshmi Vilas Bank (LVB) suspended from trading - Angel Broking

Initiating Coverage on Sundram Fasteners - Fastening growth - HDFC Securities

Astral Poly Technik - Scalability to further improve with storage tanks foray - ICICI Securities

Vardhman Special Steel - Q2FY21 Company Update - ICICI Direct

Initiating Coverage - Advanced Enzyme Technologies - ICICI Direct

L&T - Secures Large Contract - Nov 25, 2020 - Angel Broking

Alembic Pharmaceuticals - Tentative Approval for JV - Angel Broking

Drug launch by Lupin - Tacrolimus Capsules - Angel Broking

Gujarat Gas - Nov 25, 2020 - Angel Broking

Metropolis Healthcare - Nov 25, 2020 - Angel Broking

NTPC - Showcase of strength & competitiveness - ICICI Securities

Telecom - Market Share TRACKER - Bharti is narrowing the gap on incremental market share vs RJio - ICICI Securities

Cochin Shipyard - Q2FY21 Result Update - ICICI Direct

Engineers India - Q2FY21 Result Update - ICICI Direct

Rupee - Nov 24, 2020 - Reliance Securities

FMCG Sector Update - Recovery unlocked; lower growth divergence - HDFC Securities

Engineers India - Consultancy segment outperformance - ICICI Securities

Engineers India - Q2 FY21 Result Update - YES SECURITIES

Motherson Sumi Systems - Company Update - Virtual Investor Conference - ICICI Direct

Mutual Fund Review - November, 2020 - ICICI Direct

Sadbhav Engineering - Q2FY21 Company Update - ICICI Direct

IRB Infrastructure - Q2FY21 Company Update - ICICI Direct

Vodafone Idea fund raising - Angel Broking

Rupee - Nov 23, 2020 - Reliance Securities

Crude Oil - Nov 23, 2020 - Reliance Securities

Q2FY21 Bank Result Quick Review - Angel Broking

Banks & NBFC's Sector Update Report - Yet another watershed moment? - HDFC Securities

Galaxy Surfactants - EBITDA/kg has an upside risk - ICICI Securities

Diagnostics - COVID-19 tests continue to trend higher - ICICI Securities

Banking & Financial Services - Sector Update - Nov 22, 2020 - ICICI Direct

Dalmia Bharat Sugar - Q2FY21 Company Update - ICICI Direct

Balkrishna Industries - Industry export growth momentum continues - ICICI Securities

Covid Recovery Pulse - Festive positivity continues in auto retails, E-way bill generation improves... - ICICI Direct

Quant Pick - Exide Industries - ICICI Direct

Shankara Building Products - Q2FY21 Company Update - ICICI Direct

Triveni Engineering - Q2FY21 Company Update - ICICI Direct

Initiating Coverage on Sudarshan Chemical - Leaping into the league of giants - HDFC Securities

Earnings Wrap Q2FY21: Earnings outperform, post Covid recovery picks up steam - ICICI Direct

Vodafone Idea Positive development beneficial for IDFC first bank - Angel Broking

Lakshmi Vilas Bank - Angel Broking

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019